Thiogenesis Therapeutics Corp
- LAST PRICE0.6900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.6800/ 63
- Ask / Lots0.6900/ 15
- Open / Previous Close0.6800 / 0.6900
- Day Range
- 52 Week Range
- Volume16,500
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TTI |
|---|---|---|
| 09:43 ET | 14000 | 0.68 |
| 11:42 ET | 2500 | 0.69 |
Yesterday
Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium, from 9:32AM ET on Tuesday Sep 17, 2024 by Dow Jones
9:32AM ET on Tuesday Sep 17, 2024 by Dow Jones
Aug 20, 2024
Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program, from 9:03AM ET on Tuesday Aug 20, 2024 by Dow Jones
9:03AM ET on Tuesday Aug 20, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Thiogenesis Therapeutics Corp | 31.4M | -6.3x | --- |
Sona Nanotech Inc | 31.5M | -8.3x | --- |
Defence Therapeutics Inc | 24.6M | -1.6x | --- |
Resverlogix Corp | 18.0M | -1.2x | --- |
BioMark Diagnostics Inc | 21.8M | -13.1x | --- |
Sirona Biochem Corp | 20.7M | -8.2x | --- |
Company Information
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing thiol-active therapeutic compounds, which are prodrugs used to treat unmet pediatric medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. It is the active ingredient used in drugs to treat the lysosomal storage disease - (nephropathic) cystinosis. TTI-0102 has been developed to address the important obstacles facing thiol-based drugs, their short half-life, strong gastrointestinal (GI) side-effects and dosing limitations. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism. TTI-0102’s initial applications are for mitochondrial disease, Rett syndrome and pediatric non-alcoholic steatohepatitis (NASH).
Contact Information
- Headquarters
- 4 King Street West, Suite 401Toronto, ON, Canada M5H 1B6
- Phone
- 647-846-7766
- Fax
- ---
Executives
- Independent Chairman of the Board
- Christopher Starr
- Chief Executive Officer, Director
- Patrice Rioux
- Chief Financial Officer, Secretary, Director
- Brook Riggins
- Independent Director
- W. Hogan Mullally
- Independent Director
- Kim Tsuchimoto
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $31.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 45.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.11 |
Book Value | $0.12 |
P/E Ratio | -6.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
